Pure Urothelial Tumors May Predict Better NAC Response
Patients with pure urothelial carcinoma had approximately 11 times greater odds of a pT0 response.
Patients with muscle-invasive bladder cancer (MIBC) are more likely to have a complete pathologic response (pT0) to neoadjuvant chemotherapy (NAC) if they have pure urothelial carcinomas rather than cancers with variant histologic features or mixed tumors, a study found.
Venkata K. Pokuri, MD, of Roswell Park Cancer Institute in Buffalo, NY, and colleagues studied 50 robotic cystectomy patients (median age 67.5 years) who underwent NAC for MIBC. They divided patients into 2 groups: those with and without pT0. Of the 50 patients, 14 (28%) had pT0 at cystectomy, 20 (40%) had progressive disease, and 16 (32%) had residual disease.
Patients with pure urothelial carcinoma had approximately 11 times greater odds of a pT0 response compared with patients who had transitional cell variant histologic features or mixed tumors, the researchers reported online ahead of print in Clinical Genitourinary Cancer.